{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:25:43Z","timestamp":1790717143209,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The advent of biologics has resulted in major progress in the treatment of severe T2 high asthmatics. There are currently several classes of biologics approved for severe asthma including anti-immunoglobulin E, anti-interleukin-5\/interleukin 5R, anti-interleukin 4\/interleukin 13R, and anti-thymic stromal lymphopoietin.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentations<\/jats:title>\n                <jats:p>Here we report the case of a 55-year-old Caucasian man with severe eosinophilic atopic asthma, who sequentially benefited from a treatment with mepolizumab, an anti-interleukin-5 monoclonal antibody, followed by treatment with dupilumab, an anti-interleukin-4\/interleukin-13R antibody, the switch being justified by a flare-up of dermatitis while on mepolizumab. Overall, the patient has been followed for 72\u00a0months, including 42\u00a0months on mepolizumab and 30\u00a0months on dupilumab. Close monitoring of exacerbations, asthma control, lung function, asthma quality of life, and biomarkers shows that both biologics reduced asthma exacerbation and provided an improvement in asthma control and quality of life, with the patient achieving remission after 30\u00a0months on dupilumab. However, the effects of the two biologics on the biomarkers were very different, with mepolizumab controlling eosinophilic inflammation and dupilumab reducing serum immunoglobulin E and fractional exhaled nitric oxide levels.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The originality of this case resides in the description of clinical status and biomarker evolution after a sequential use of mepolizumab and dupilumab in a severe atopic eosinophilic asthmatic. It shows that mepolizumab reduces exacerbation and improves asthma control by curbing eosinophilic inflammation whereas dupilumab provides asthma remission without controlling airway eosinophilic inflammation.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-023-04255-8","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T01:02:38Z","timestamp":1706662958000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["When sequential use of mepolizumab and dupilumab in a severe atopic eosinophilic asthmatic questions the role of eosinophils in mediating the clinical expression of the disease: a case report"],"prefix":"10.1186","volume":"18","author":[{"given":"M.","family":"Sabbe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Schleich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Janssens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Louis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,31]]},"reference":[{"issue":"9","key":"4255_CR1","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1136\/thx.54.9.825","volume":"54","author":"KF Chung","year":"1999","unstructured":"Chung KF, Barnes PJ. Cytokines in asthma. Thorax. 1999;54(9):825\u201357.","journal-title":"Thorax"},{"key":"4255_CR2","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/S0140-6736(15)00157-9","volume":"386","author":"KF Chung","year":"2015","unstructured":"Chung KF. Target the interleukin pathway in the treatment of asthma. Lancet. 2015;386:1086\u201396.","journal-title":"Lancet"},{"issue":"4","key":"4255_CR3","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1164\/rccm.201810-1944CI","volume":"199","author":"MC McGregor","year":"2019","unstructured":"McGregor MC, Krings JG, Nair P, Castro M. Role of biologics in asthma. Am J Respir Crit Care med. 2019;199(4):443\u20135.","journal-title":"Am J Respir Crit Care med"},{"issue":"5","key":"4255_CR4","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1111\/all.14235","volume":"75","author":"I Agache","year":"2020","unstructured":"Agache I, Beltran J, Akdis C, Akdis M, Canelo-Aybar C, WalterCanonica G, Casale T, Chivato T, Corren J, Del Giacco S, Eiwegger T, Firinu D, Gern JE, Hamelmann E, Hanania N, M\u00e4kel\u00e4 M, Hernandez-Martin I, Nair P, O\u2019Mahony L, Papadopoulos NG, Papi A, Park H-S, Perez de Liano L, Posso M, Rocha C, Quirce S, Sastre J, Shamji M, Song Y, Steiner C, Schwarze J, Alonso-Coello P, Palomares O, Jutel M. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: a systematic review for the EAACI Guidelines\u2014recommendations on the use of biologicals in severe asthma. Allergy. 2020;75(5):1043\u201357.","journal-title":"Allergy"},{"key":"4255_CR5","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1056\/NEJMra2032506","volume":"386","author":"G Brusselle","year":"2022","unstructured":"Brusselle G, Koppelman G. Biologic therapies for asthma. N England J Med. 2022;386:157\u201371.","journal-title":"N England J Med"},{"key":"4255_CR6","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1056\/NEJMoa1215372","volume":"368","author":"M Maurer","year":"2013","unstructured":"Maurer M, Rosen K, Hsieh H, Saini S, Grattan C, Gimenez-Arnau A, Agarwal S, Doyle R, Canvin J, Kaplan A, Casale T. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368:324\u2013935.","journal-title":"N Engl J Med"},{"key":"4255_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/cea.13491","volume":"50","author":"H Harb","year":"2020","unstructured":"Harb H, Chatila TA. Mechanisms of dupilumab. Clin Exp Allergy. 2020;50:5\u201314.","journal-title":"Clin Exp Allergy"},{"key":"4255_CR8","doi-asserted-by":"publisher","first-page":"873","DOI":"10.2147\/JAA.S258438","volume":"14","author":"JC Morse","year":"2021","unstructured":"Morse JC, Miller C, Senior B. Management of chronic rhinosinutis with nasal polyposis in the era of biologics. J Asthma Allergy. 2021;14:873\u201382.","journal-title":"J Asthma Allergy"},{"issue":"10","key":"4255_CR9","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","volume":"9","author":"JK Han","year":"2021","unstructured":"Han JK, Bachert C, Fokkkens W, Lee SE, Smith SG, Martin N, Mayer B, Yancey SW, Sousa AR, Cham R, Hopkins C. Mepolizumab for chronic rhinosinutis with nasal polyps (synapse): a randomised double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;9(10):1141\u201353.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"4255_CR10","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1056\/NEJMoa0808991","volume":"360","author":"P Haldar","year":"2009","unstructured":"Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, Parvord ID. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360(1):973\u201384.","journal-title":"N Engl J Med."},{"issue":"9","key":"4255_CR11","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.3390\/biomedicines9091281","volume":"9","author":"L Calzetta","year":"2021","unstructured":"Calzetta L, Aiello M, Frizzelli A, Bertorelli G, Ritondo BL, Rogliani P, Chetta A. The impact of monoclonal antibodies on airway smooth muscle contractility in asthma: a systematic review. Biomedicines. 2021;9(9):1281.","journal-title":"Biomedicines"},{"issue":"1","key":"4255_CR12","doi-asserted-by":"publisher","first-page":"e01074","DOI":"10.1002\/rcr2.1074","volume":"11","author":"M Anai","year":"2022","unstructured":"Anai M, Yoshida C, Izumi H, Muramoto K, Saruwatari K, Tomita Y, Ichiyasu H, Sakagami T. Successful treatment with dupilumab for mucus plugs in severe asthma. Respirol Case Rep. 2022;11(1):e01074.","journal-title":"Respirol Case Rep."},{"issue":"10","key":"4255_CR13","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/S2213-2600(20)30190-9","volume":"8","author":"HAM Kerstjens","year":"2020","unstructured":"Kerstjens HAM, Maspero J, Chapman KR, van Zyl-Smit RN, Hosoe M, Tanase A-M, Lavecchia C, Pethe A, Shu X, D\u2019Andrea P. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. Lancet Respir Med. 2020;8(10):1000\u201312.","journal-title":"Lancet Respir Med"},{"issue":"3","key":"4255_CR14","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jaci.2019.12.006","volume":"145","author":"A Menzies-Gow","year":"2020","unstructured":"Menzies-Gow A, Bafadhel M, Busse WW, Casale TB, Kocks JWH, Parvord ID, Szefler SJ, Woodruff PG, de Giorgio-Miller A, Trudo F, Fageras M, Ambrose CS. An expert consensus framework for asthma remission as a treatment goal. J Allergy Clin Immunol. 2020;145(3):757\u201365.","journal-title":"J Allergy Clin Immunol"},{"key":"4255_CR15","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/all.14151","volume":"75","author":"A Le Floc\u2019h","year":"2020","unstructured":"Le Floc\u2019h A, Allinne J, Nagashima K, Scott G, Birchard D, Asrat S, Bai Y, Lim WK, Martin J, Huang T, Potocky TB, Kim JH, Rafique A, Papadopoulos NJ, Stahl N, Yancopoulos GD, Murphy AJ, Sleeman MA, Orengo JM. Dual blockade of Il-4 and Il-13 with dupilumab, an il-4Ralpha antibody, is required to broadly inhibit type 2 inflamation. Allergy. 2020;75:1188\u2013204.","journal-title":"Allergy"},{"issue":"26","key":"4255_CR16","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","volume":"368","author":"S Wenzel","year":"2013","unstructured":"Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, Wang L, Kirkesseli S, Rocklin R, Bock B, Hamilton J, Ming JE, Radin A, Stahl N, Yancopoulos GD, Graham N, Pirozzi G. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368(26):2455\u201366.","journal-title":"N Engl J Med"},{"issue":"7","key":"4255_CR17","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","volume":"4","author":"HG Ortega","year":"2016","unstructured":"Ortega HG, Yancey SW, Mayer B, Gunsoy NB, Keene ON, Bleecker ER, Brigthling CE, Parvord ID. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophilic thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016;4(7):549\u201356.","journal-title":"Lancet Respir Med"},{"issue":"6","key":"4255_CR18","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/cea.13601","volume":"50","author":"F Schleich","year":"2020","unstructured":"Schleich F, Graff S, Nekoee H, et\u00a0al. Real-word experience with mepolizumab: does it deliver what it has promised? Clin Exp Allergy. 2020;50(6):687\u201395.","journal-title":"Clin Exp Allergy"},{"issue":"6","key":"4255_CR19","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.chest.2023.01.037","volume":"163","author":"C Moermans","year":"2023","unstructured":"Moermans C, Brion C, Bock G, Graf S, Gerday S, Nekoee H, Poulet C, Bricmont N, Henket M, Paulus V, Guissard F, Louis R, Schleich F. Sputum Type 2 markers could predict remission in severe asthma treated with anti-IL-5. Chest. 2023;163(6):1368\u201379.","journal-title":"Chest"},{"key":"4255_CR20","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","volume":"378","author":"M Castro","year":"2018","unstructured":"Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sherb L, FitzGerald JM, Katelaris C, Tohda Y, Zhang B, Staudiger H, Pirozzi G, Amin N, Ruddy M, Akinlande B, Khan A, Chao J, Martincova R, Graham NMH, Hamilton JD, Swanson BN, Stahl N, Yancopoulos GD, Teper A. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378:2486\u201396.","journal-title":"N Engl J Med."},{"issue":"1","key":"4255_CR21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1097\/ACI.0000000000000490","volume":"19","author":"AY Wu","year":"2019","unstructured":"Wu AY, Sur S, Grant JA, Tripple JW. Interleukin-4\/interleukin-13 versus interleukin-5: a comparison of molecular targets in biologic therapy for the treatment of severe asthma. Curr Opin Allergy Immunol. 2019;19(1):30\u20137.","journal-title":"Curr Opin Allergy Immunol"},{"issue":"2","key":"4255_CR22","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/rr40","volume":"2","author":"JW Steinke","year":"2001","unstructured":"Steinke JW, Borish L. Th2 cytokines and asthma. Interleukin-4: its role in the pathogenesis of asthma and targeting it for asthma treatment with interleukin-4 receptor antagonists. Respir Res. 2001;2(2):66\u201370.","journal-title":"Respir Res"},{"key":"4255_CR23","unstructured":"ClinicalTrials.gov Identifier: NCT02573233."},{"issue":"9","key":"4255_CR24","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1172\/JCI85664","volume":"126","author":"C Mesnil","year":"2016","unstructured":"Mesnil C, Raulier S, Paulissen G, Xiao X, Birrell MA, Pirottin D, Jamess T, Starkl P, Ramery E, Henket M, Schleich FN, Radermacker M, Thielemans K, Gillet L, Thiry M, Belvisi MG, Louis R, Desmet C, Marechal T, Bureau F. Lung-resident eosinophils represent a district regulatory eosinophil subset. J Clin Invest. 2016;126(9):3279\u201395.","journal-title":"J Clin Invest"},{"key":"4255_CR25","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2147\/JAA.S275068","volume":"13","author":"ID Pavord","year":"2020","unstructured":"Pavord ID, Siddiqui S, Papi A, Corren J, Sher DL, Baffin P, Langton D, Park H, Rice MS, Deniz Y, Rowe P, Staudinger HW, Patel N, Ruddy M, Graham NMH, Teper A. Dupilumab efficacy in patients stratified by baseline treatment intensity and lung function. J Asthma Allergy. 2020;13:701\u201311.","journal-title":"J Asthma Allergy"},{"issue":"7","key":"4255_CR26","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1111\/cea.13954","volume":"51","author":"JD Hamilton","year":"2021","unstructured":"Hamilton JD, Harel S, Swanson BN, Brian W, Chen Z, Rice MS, Amun N, Ardeleanu M, Radin A, Shumel B, Ruddy M, Patel N, Pitozzi G, Mannent L, Graham NMH. Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases. Clin Exp Allergy. 2021;51(7):915\u201331.","journal-title":"Clin Exp Allergy"},{"issue":"12","key":"4255_CR27","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1136\/thx.2009.124925","volume":"65","author":"FN Schleich","year":"2010","unstructured":"Schleich FN, Seidel L, Sele J, Manise M, Quaedvlieg V, Michils A, Louis R. Exhaled nitric oxide threshold associated with a sputum eosinophil count >3% in a cohort of unselected patients with asthma. Thorax. 2010;65(12):1039\u201344.","journal-title":"Thorax"},{"issue":"6","key":"4255_CR28","doi-asserted-by":"publisher","first-page":"100655","DOI":"10.1016\/j.waojou.2022.100655","volume":"15","author":"S Gerday","year":"2022","unstructured":"Gerday S, Schleich F, Henket M, Guissard F, Paulus V, Louis R. Revisiting differences between atopic and non-atopic asthmatics: when age is shaping airway inflammatory profile. World Allergy Organ J. 2022;15(6):100655.","journal-title":"World Allergy Organ J"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-023-04255-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-023-04255-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-023-04255-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T01:03:26Z","timestamp":1706663006000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-023-04255-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,31]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4255"],"URL":"https:\/\/doi.org\/10.1186\/s13256-023-04255-8","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,31]]},"assertion":[{"value":"22 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"R. Louis reports grants and personal fees from GSK, AZ, Chiesi, and Novartis and personal fees from Sanofi outside the submitted work. F. Schleich reports grants and personal fees for national board participation and presentations from GSK and AstraZeneca and personal fees for board participation and lectures from Chiesi outside the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"63"}}